[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"RESnTEC, Institute of Research\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100556999","comparison-of-efficacy-of-oral-amoxicillin-versus-intravenous-ceftriaxone-100556999",false,"NCT06532409","Comparison of Efficacy of Oral Amoxicillin Versus Intravenous Ceftriaxone","Efficacy of Oral Amoxicillin in Comparison to Intravenous Ceftriaxone in Treatment of Uncomplicated Community Acquired Pneumonia (Cap) Among Children of Age 2-5 Years of Age","Inclusion Criteria:\n\n* Children of both gender\n* Aged from 2 to 5 years\n* With fever \\>37.5 C (99.5 F)\n* Will be presented with symptoms and signs of uncomplicated community acquired pneumonia\n\nExclusion Criteria:\n\n* Children requiring ICU care (having cyanosis SpO2 \\\u003C 85% requiring intubation within first day of admission or in state of shock)\n* Children with conditions like congenital heart disease, chronic lung disease, chronic kidney disease, severe malnutrition, asthma, foreign bodies, sickle cell disease, and immunodeficiency\n* Children with underlying anatomical disorders of the lung like pulmonary sequestration, tracheoesophageal fistula or congenital cystic adenoid malformation\n* Children already on antibiotics\n* Presence of any complication of community acquired pneumonia\n* Patients having symptoms of multi-organ involvement\u002Fsepsis\n* Hypersensitivity to Amoxicillin or Ceftriaxone\n* Other co-existing infections like dengue, malaria, or measles","ALL","2 Years","5 Years",{"count":20,"type":21},114,"ESTIMATED","INTERVENTIONAL",[24],"NA","The efficacy of oral amoxicillin is considered equal to that of ceftriaxone in community-acquired pneumonia among children. Also, there are some factors that contradict the usage of ceftriaxone, like antibiotic resistance, adverse reactions, drug cost, and the and the chances of IV trauma and infection, which is a major problem in developing countries. Therefore, this study was planned to determine the efficacy of oral amoxicillin compared with intravenous (IV) ceftriaxone in the treatment of uncomplicated ceftriaxone in community acquired pneumonia in children less than 5 years of age.",[27],"Community-acquired Pneumonia","NOT_YET_RECRUITING","2024-07-31",{"date":31,"type":32},"2024-08-01","ACTUAL",{"date":34,"type":21},"2024-10-01",{"date":36,"type":21},"2025-09-30",{"name":38,"class":39},"RESnTEC, Institute of Research","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100553888","comparison-of-the-role-of-losartan-alone-vs-hydrochlorothiazide-plus-losartan-100553888","NCT06491940","Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan","Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan on Proteinuria in Diabetic Nephropathy Patients","Inclusion Criteria:\n\n* Patients of both genders with ≥18 years of age.\n* Presence of proteinuria\u002Falbuminuria at time of screening.\n* Creatinine clearance of 30 mL\u002Fmin or higher.\n\nExclusion Criteria:\n\n* A systolic blood pressure of 180 mm Hg or higher, a diastolic blood pressure of 110 mm Hg or higher.\n* Presence of a second primary renal disease in addition to diabetic nephropathy.\n* Patients with type 1 diabetes.\n* A history of a cardiovascular or cerebrovascular event within 3 months before inclusion.\n* Serum potassium of 6.0 mmol\u002FL or higher.\n* Transplantation or immunosuppressive treatment.\n* Contraindication for the use of losartan or hydrochlorothiazide.\n* Pregnancy or lactation.","18 Years","75 Years",{"count":51,"type":21},234,[24],"Losartan, an angiotensin II receptor blocker, has already been established as a treatment for diabetic nephropathy due to its ability to reduce blood pressure and mitigate the progression of kidney damage. However, the addition of a diuretic like hydrochlorothiazide may offer synergistic benefits in reducing proteinuria by addressing both the underlying renal pathology and potential volume overload in these patients. The current study aims at determining and comparing the role of losartan alone vs hydrochlorothiazide plus losartan in reducing proteinuria in diabetic nephropathy patients.",[55],"Proteinuria","2024-07-01",{"date":58,"type":32},"2024-07-09",{"date":31,"type":21},{"date":61,"type":21},"2025-07-31",{"name":38,"class":39},""]